ACE2 and COVID-19: The expression of ACE2 is higher in patients with diabetes and hypertension, who are treated with ACE inhibitors and angiotensin II type-I receptor blockers and thus the increased expression of ACE2 makes the lungs more vulnerable to injury and facilitates infection with COVID-19 with increased chances of respiratory failure 36.